Live feed16:05:00·21mPRReleasevia QuantisnowPublication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic InhibitionByQuantisnow·Wall Street's wire, on your screen.IMRX· Immuneering CorporationHealth Care
